Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.
MHC class II deficiency provokes a severe immunodeficiency characterized by a lack of antigen-specific immune response. In the absence of bone marrow transplantation (the only curative treatment), patients affected by this genetic recessive disease die in early childhood. However, others and we have recently described cases of mild or asymptomatic immunodeficiencies with defects in either CIITA (class II transactivator) or RFX5, both proteins required for the transcription of HLA-D genes. We describe in this report the first case of moderate immunodeficiency resulting from a defect in RFXANK, another transcription factor essential for HLA-D expression. The patient did not display any detectable expression of MHC class II molecules on B lymphocytes, monocytes or activated T lymphocytes. Accordingly HLA-D transcription was altered in the corresponding B-lymphoblastoid cell line. The defect in RFXANK was observed both at the transcript and protein level. Indeed a homozygous IVS4+5G>A mutation was evidenced in RFXANK, and shown to hamper the splicing of intron 4. However, we had shown previously that a defect in intron 4 can lead to the skipping of exon 4, and that the resulting truncated protein retains the capacity to activate HLA-DR expression. Therefore, like the two cases of moderate immunodeficiencies described previously, we demonstrate that the RFXANK defect presented here is coherent with a residual activity of the mutant protein. We thus propose that the common feature displayed by mildly immunodeficient patients is the leakiness of the mutations, which might allow a local or temporal expression of MHC class II molecules.
INSERM U396, Centre de Recherches Biomedicales des Cordeliers, 15 rue de l'Ecole de Medecine, 75006 Paris, France.
Thomas
T
Prod'homme
Benjamin
B
Dekel
Giovanna
G
Barbieri
Barbara
B
Lisowska-Grospierre
Rina
R
Katz
Dominique
D
Charron
Catherine
C
Alcaide-Loridan
Shimon
S
Pollack
D000328:Adult; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D019556:COS Cells; D004268:DNA-Binding Proteins; D005260:Female; D006681:HLA-D Antigens / Q000235:genetics; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000235:genetics* / Q000276:immunology; D009154:Mutation; D012326:RNA Splicing; D014157:Transcription Factors / Q000235:genetics*; D014162:Transfection
D004268:DNA-Binding Proteins; D006681:HLA-D Antigens; D000949:Histocompatibility Antigens Class II; C117892:RFXANK protein, human; D014157:Transcription Factors